Imatinib Completed Phase 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00193180Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
NCT00087152S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer